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Abstract
Background: Clinical practice guidelines recommend ad hoc screening of diabetes in patients 
admitted for macrovascular disease; however, these recommendations are rarely followed in 
real practice. This study was undertaken to assess whether impaired glucose metabolism, newly  
diagnosed after percutaneous coronary intervention (PCI) or known diabetes, provides pro­
gnostic information.
Methods: We studied 374 patients who underwent PCI. An oral glucose tolerance test was 
carried out in the known non­diabetic patients with fasting glucose < 7 mmol/L.
Results: Eighty­one percent of the patients presented impaired glucose metabolism, from 
which 35.3% were previously diagnosed with diabetics, 21.4% were newly detected diabetics, 
and 24.3% were pre­diabetics. After a mean follow­up of 35.8 ± 13.4 months, only a known 
history of diabetes was an independent predictor of revascularization (OR = 2.03, p = 0.025), 
non­fatal acute myocardial infarction (OR = 2.70, p = 0.029) and readmission due to heart 
failure during the follow­up (OR = 3.82, p = 0.022).
Conclusions: Screening for impaired glucose metabolism after PCI permits the detection of 
a high proportion of patients with abnormal glucose regulations. However, previously known 
diabetes remains the only independent predictor of cardiovascular events in the follow­up. 
(Cardiol J 2015; 22, 1: 44–51)
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Introduction
According to Euro Heart Survey Program [1] 
and other epidemiological data, the prevalence of 
diabetes mellitus (DM) in adults increased, the 
number of individuals affected with DM also incre-
ased and other data show a consistent increase of 
the number of people with DM and cardiovascular 
disease (CVD) [1, 2]. There is also an increased 
number of diabetics receiving percutaneous coro-
nary intervention (PCI) [3]. The rising prevalence 
of DM is followed by an increasing prevalence of 
CVD morbidity and mortality. In the last decade, 
all-cause and cause specific mortality rates declined 
in all patients, although not in patients with DM 
[2]. These data suggest that increases in DM rates 
threaten the long-established nationwide trend 
towards reduced coronary artery events.
Diabetes and carbohydrate intolerance 
increase cardiovascular risk [4, 5]. Indeed, Euro 
Heart Survey data show a high proportion of 
impaired glucose metabolism, which could influ-
ence prognosis [6] among patients suffering from 
ischemic heart disease. This is why European gu-
idelines [7], unlike the proposals of the American 
Diabetes Association (ADA) [8], recommend ad hoc 
screening of patients admitted for macrovascular 
disease by means of an oral glucose tolerance 
test that provides more precise information about 
fasting glucose. Although it is accepted as a valid 
option for the diagnosis of diabetes, glycated he-
moglobin (HbA1c), when used in isolation, may give 
incorrect results under certain conditions, which is 
why recommendations are fundamentally based on 
carrying out an oral glucose tolerance test (OGTT) 
[7, 9]. For the diagnosis of diabetes, the OGTT is 
a more sensitive and better predictor of CVD than 
fasting glucose [9–11]. Nevertheless, despite being 
the best tool available, it does not wholly fulfil the 
characteristics of speed, simplicity, and reprodu-
cibility that are desirable in every screening test, 
and in habitual clinical practice guidelines are 
rarely followed.
On the other hand, the significance of heart 
disease in our population in absolute terms is 
well-known, as is how coronary revascularization 
procedures have shown prognostic improvement 
for many CVD in global terms and for diabetics in 
particular [12]. Therefore, given the large number 
of procedures that are carried out, this could be 
a suitable occasion for ad hoc screening for impaired 
glucose metabolism.
The objective of this study was to assess 
whether impaired glucose metabolism, newly 
detected, versus known diabetics with coronary ar-
tery disease admitted for PCI provides prognostic 
information in terms of cardiovascular events and 
mortality during follow-up compared to a previou-
sly recognized diagnosis of diabetes.
Methods
Population
The patients included in this study underwent 
PCI in the context of stable angina with inducible 
ischemia or symptoms refractory to medical treat-
ment, or with acute coronary syndrome (ACS) (with 
or without ST segment elevation) in our center 
(n = 377). Unstable angina and non-ST-elevation 
ACS (NSTE-ACS) were defined by electrocar-
diographic ST segment depression or prominent 
T-wave inversion and/or positive biomarkers of 
necrosis in the absence of ST-segment elevation 
and in an appropriate clinical setting (chest discom-
fort or anginal equivalent). ST-elevation myocardial 
infarction (STEMI) was defined by the presence of 
ischemic symptoms and persistent electrocardio-
graphic ST segment elevation.
Exclusion criteria: hemodynamic instability 
(Killip III–IV), post-PCI transferral of the patient 
to the hospital of origin, treatment with glucose 
metabolism modifying drugs (glucocorticoids, 
thiazide diuretics, levothyroxine and niacin), any 
allergy to dual antiplatelet therapy, patient’s refusal 
or failure to sign informed consent.
Study protocol
A prospective longitudinal observational study 
was designed. All patients underwent diagnostic 
therapeutic cardiac catheterization via the femoral or 
radial artery using the Seldinger technique, and the 
SYNTAX score [13] was applied to estimate the ex-
tent and complexity of coronary heart disease. The 
score was independently determined by 2 specialists 
in hemodynamics. As defined in the inclusion crite-
ria, all patients underwent PCI while admitted. Left 
ventricular ejection fraction (LVEF) was quantified 
by means of a contrast ventriculography and/or via 
echocardiography, using Simpson’s rule (Acuson 
Sequoya, Siemens AG, Munich, Germany). All of the 
patients were informed about the nature of the study 
and gave their written consents, and the study was 
reviewed and approved by the Ethics and Research 
Committees of our hospital.
Definition of glucometabolic status
Among the included patients, we considered 
known diabetics to be those who had a previously 
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recognized diagnosis of this pathology, regardless 
of the use of pharmacological treatment. Fasting 
plasma glucose (after 8 h with no calorie intake) and 
levels of HbA1c were determined for these known 
diabetics (n = 132).
Fasting plasma glucose for patients with 
no previous diagnosis of diabetes was determi-
ned the morning after percutaneous coronary 
revascularization. Patients with fasting glucose 
< 7 mmol/L were given an OGTT using 75 g 
of anhydrous glucose, with fasting plasma glucose 
determined before the test and plasma glucose 2 h 
after intake. Thus, it was possible to categorize the 
patients with no previously recognized diagnosis of 
diabetes as follows, in accordance with American 
Diabetes Association (ADA) classifications [8]:
—  Patients with normal glucose metabolism: tho-
se with fasting plasma glucose < 5.6 mmol/L, 
plasma glucose < 7.8 mmol/L 2 h after the 
OGTT (n = 71);
—  Pre-diabetics: those with fasting plasma glu-
cose of 5.6–6.9 mmol/L (impaired fasting glu-
cose) or plasma glucose 7.8–11.0 mmol/L 2 h 
post-intake (intolerance to glucose) (n = 91);
—  Newly detected diabetics: patients were con-
sidered as such if they had no known history 
of diabetes and presented a fasting plasma 
glucose ≥ 7 mmol/L or plasma glucose 
≥ 11.1 mmol/L 2 h post-intake (n = 65).
Follow-up
Clinical follow-up of all included patients was 
carried out in person or by phone. During follow-
-up we recorded events, which included the need 
for coronary revascularization, readmission due 
to unstable angina or non-fatal acute myocardial 
infarction (AMI) or heart failure (HF), and cardio-
vascular mortality. A record was also kept of the 
incidence of cerebrovascular accidents and morta-
lity due to any cause during follow-up.
Statistical analysis
Continuous variables are expressed as a mean 
± standard deviation and categorical variables as 
percentages. Normal distribution of quantitative 
variables was checked using the Shapiro-Wilk 
test. In the case of normality, Levene’s test was 
applied to compare variance; where variances 
were equal, Student’s t-test was used to compare 
the averages; if variances were different, Welch’s 
test was used for the comparison. In the absence 
of normality, the Mann-Whitney test was applied 
to compare averages. We used the ANOVA test to 
compare quantitative variable means between more 
than two groups. The c2 test was used to compare 
qualitative variables. A two sided value of p < 0.05 
was considered significant. Multivariate analysis 
was made using a multiple logistic regression mo-
del to identify independent variables predictive of 
adverse events in follow-up. The model included 
those variables that reached a statistical signifi-
cance level of 0.15 in the univariate analysis and 
known variables related with prognosis. The odds 
ratio (OR) and 95% confidence intervals (CI) were 
calculated from the parameters estimated by the 
regression model. All statistical analysis was made 
using the SPSS program (version 11.0, SPSS Inc., 
Chicago, IL, USA).
Results
Characteristics of the population
Three hundred and seventy-seven patients 
met the criteria during the inclusion period and 
agreed to participate in the study and 3 were 
excluded due to deviations in the intake protocol 
which prevented definition of their glucometabolic 
status, thus 374 patients were finally included in 
the analysis.
The mean age of the sample was 62.67 ± 
± 10.72 years, and 77.3% were male. The indica-
tion for coronarography was NSTE-ACS in 52.7% 
of patients, with ST elevation (STE-ACS) in 27.3% 
and stable stress angina in 19.8%.
The 81% of included patients presented im-
paired glucose metabolism, of which percentage 
35.29% were previously diagnosed diabetics, 
21.39% newly detected diabetics and 24.33% pre-
-diabetics.
Basal characteristics of the patients, categori-
zed according to the presence of impaired glucose 
metabolism are shown in Table 1. The previously 
recognized diabetic patients were older, with a lower 
percentage of men, and the predominant indication 
for coronarography was NSTE-ACS. With regard 
to pharmacological treatment, the diabetic patients 
more frequently received glycoprotein IIb/IIIa 
inhibitors (53% of recognized diabetic patients vs. 
28.1% of the total of patients with no known history 
of DM, p < 0.0001), and angiotensin-converting 
enzyme inhibitors or angiotensin II receptor an-
tagonists (77.3% of known diabetics vs. 62% of 
patients with no known history of DM, p = 0.003) 
without the existence of significant differences in 
other treatments. The average SYNTAX score for 
the total of patients was 11.29 ± 7.73. When com-
parisons were made of the glucometabolic status 
between the four groups, the score increased in pa-
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rallel with the presence of impaired glucose meta-
bolism in a statistically significant way (p = 0.004); 
85.3% of patients received drug-eluting stents, 
reaching 91.7% among diabetic patients. None of 
the included patients died while admitted and dis-
charged after an average stay of 5.01 ± 3.74 days.
The prognostic implications of  
impaired glucose metabolism
After a mean follow-up of 35.84 ± 13.43, du-
ring which months there was a loss of 12 (3.20%) 
patients, 47 (13%) patients required a new per-
cutaneous or surgical revascularization, there 
were 32 (8.8%) readmissions for unstable angina, 
21 (5.8%) for non-fatal AMI, 15 (4.1%) for HF, and 
13 (3.6%) deaths attributable to cardiovascular 
causes. Seven (1.9%) patients suffered a non-fatal 
cerebrovascular accident and global mortality was 
4.7%. The events during follow-up in the different 
glucose metabolism categories are shown in Table 2. 
Previously known diabetic patients had higher 
rates of complications than non-known diabetic 
patients. We appreciate a growing trend towards 
the incidence of readmission for HF, in parallel with 
the magnitude of glucose metabolism impairment 
(8.1% of known diabetics, 3.8% of newly detected 
diabetic patients, 2.2% of pre-diabetic patients and 
0% of patients with normal glucose metabolism, 
Table 1. Baseline characteristics.
Normal
(n = 71)
Pre-diabetes
(n = 91)
Newly 
detected
diabetes
(n = 80)
Known 
diabetes
(n = 132)
p* p†
Age [years] 55.95 ± 10.93 62.98 ± 10.91 63.01 ± 9.79 66.64 ± 9.14 < 0.0001 < 0.0001
Gender (male) 95.8% 78.0% 81.3% 64.4% < 0.0001 < 0.0001
Hypertension 59.2% 49.5% 53.8% 70.5% 0.009 0.002
Smoker 49.3% 30.8% 46.3% 40.9% 0.077 < 0.0001
HbA1c [%] 5.02 ± 0.43 5.05 ± 0.47 5.28 ± 0.59 5.32 ± 0.71 0.020 0.010
Dyslipidemia 56.3% 50.5% 45% 60.6% 0.137 0.059
Chronic kidney disease 0% 6.6% 5% 6.1% 0.197 0.400
Prior IHD 32.4% 33% 40% 47.7% 0.076 0.017
Prior coronary revascularization:
Percutaneous 11.3% 9.9% 10.0 12.9 0.510 0.100
Surgical 4.2% 2.2% 3.8 3.8
Both 0% 0% 1.3 3.8
Clinical presentation:
Stable angina
NSTE-ACS
STE-ACS
12.7%
45.1%
42.3%
15.4%
59.3%
25.3%
26.3%
38.8%
35.0%
21.2%
60.6%
16.7%
< 0.0001 < 0.0001
In hospital treatment:
IIb/IIIa inhibitors
Beta-blockers
ACEI/ARB
Statins
36.6%
84.5%
63.4%
88.7%
24.2%
82.4%
60.4%
82.4%
25%
86.3%
62.5%
82.5%
53.8%
86.4%
77.3%
84.1%
< 0.0001
0.854
0.026
0.685
< 0.0001
0.590
0.030
0.950
Syntax score 9.97 ± 6.20 9.88 ± 6.63 10.92 ± 7.54 13.17 ± 8.88 0.004 0.001
Left ventricular dysfun-
ction (LVEF < 50%)
37.5% 31.8% 29.5% 41.9% 0.319 0.012
Stent: 
Bare metal stent
Drug eluting stent
Both
18.3%
76.1%
5.6%
23.1%
67.0%
8.8%
17.5%
76.3%
6.3%
4.5%
91.7%
3.8%
0.003 < 0.0001
*p value in comparison between the four groups; †p value of the comparison between known diabetics and all the remaining patients;  
IHD — ischemic heart disease; NSTE-ACS — non-ST-elevation acute coronary syndrome; STE-ACS — ST-elevation acute coronary syndrome; 
ACEI — angiotensin converting enzyme inhibitors; ARB — angiotensin receptors blockers; LVEF — left ventricular ejection fraction
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p = 0.03). We also appreciate a greater incidence of 
non-fatal myocardial infarction in known-diabetics 
patients (12% vs. 3%, p < 0.023).
We established a comparative analysis of the 
distribution of clinical, metabolic, and angiographic 
characteristics compared with the different cardio-
vascular events (revascularization, unstable angina, 
non-fatal heart attack and cardiovascular mortality 
in follow-up) (Table 3). Among the patients who 
required a new revascularization in follow-up, there 
was a lower percentage of pre-diabetics (12.8% 
of pre-diabetics in the patients who needed new 
Table 2. Events on follow-up.
Normal
(n = 69)
Pre-diabetes
(n = 90)
Newly detected
diabetes
(n = 79)
Known diabetes
(n = 124)
p* p†
Revascularization 10.1 (7) 6.7 (6) 13.9 (11) 18.5 (23) 0.06 0.023
Unstable angina 8.7 (6) 6.7 (6) 8.9 (7) 10.5 (13) 0.810 0.420
Non-fatal AMI 4.3 (3) 3.3 (3) 3.8 (3) 9.7 (12) 0.15 0.023
Heart failure 0 (0) 2.2 (2) 3.8 (3) 8.1 (10) 0.030 0.007
CV mortality 2.9 (2) 2.2 (2) 3.8 (3) 4.8 (6) 0.760 0.350
Stroke 0 (0) 1.1 (1) 3.8 (3) 2.4 (3) 0.350 0.620
All-cause mortality 2.9 (2) 2.2 (2) 6.3 (5) 6.5 (8) 0.380 0.250
*p value in the comparison between the four groups; †p value of the comparison between known diabetics and all the remaining patients.  
Absolute numbers of events are provided between parentheses; AMI — acute myocardial infarction; CV — cardiovascular
Table 3. Univariate analysis of events on follow-up.
Revascularization Unstable angina Non-fatal AMI Heart failure CV mortality
No Yes No Yes No Yes No Yes No Yes
Age [years] 
(mean)
62.87% 63.34% 62.63% 66.12% 63.0% 61.95% 62.68% 68.86%† 62.64% 70.76%
Gender (male) 78.10% 66.0% 78.80% 53.10%† 77.10% 66.70% 77.70% 60.0% 76.80% 69.20%
Hypertension 59.40% 66.0% 58.80% 75.0% 59.80% 66.70% 59.40% 80.0% 60.5% 53.8%
Smoker 41.60% 36.20% 43.0% 18.80%* 41.10% 38.10% 40.90% 40.0% 41.5% 23.1%
Dyslipidemia 54.60% 57.40% 55.50% 50.0% 54.0% 71.4% 54.20% 73.30% 55.3% 46.2%
Creatinine  
level on admi- 
ssion (mean) 
[μmol/L]
81.20% 91.93% 82.21% 91.05% 82.21% 98.12% 83.09% 79.56% 82.21% 89.28%
Carbohydrate metabolism:
Normal 19.70% 14.90% 19.10% 18.80% 19.4% 14.3% 19.90% 0%† 19.20% 15.40%
Pre-diabetes 26.70% 12.80%* 25.50% 18.80% 25.50% 14.30% 25.40% 13.30% 25.20% 15.40%
Newly  
detected  
diabetes
21.60% 23.40% 21.80% 21.90% 22.30% 14.30% 21.90% 20.0% 21.80% 23.10%
Known  
diabetes
32.10% 48.90%* 33.60% 40.60% 32.80% 57.0%* 32.90% 66.70%† 33.80% 46.20%
Clinical presentation:
SA 19.40% 27.70% 20.0% 25.0% 19.40% 38.10%* 19.30% 46.70%* 20.90% 7.70%
ACS 80.60% 72.30% 80.0% 75.0% 80.60% 61.90%* 80.70% 53.30%* 79.10% 92.30%
EF (mean) 55.29% 56.20% 55.26% 57.0% 55.49% 54.0% 55.85% 45.53%† 55.67% 47.27%
SYNTAX  
score (mean)
11.30% 11.88% 11.46% 10.43% 11.23% 13.71% 11.22% 14.93% 11.12% 18.11%
*p < 0.05; †p < 0.01; AMI — acute myocardial infarction; CV — cardiovascular; SA — stable angina; ACS — acute coronary syndrome;  
EF — ejection fraction
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revascularization and 26.7% among those who did 
not need one, p = 0.04), a greater proportion of 
known diabetics (48.9% in patients revasculari-
zed during follow-up vs. 32.1% among the non-
-revascularized), and a lower proportion of males, 
although statistical significance was not reached 
(66% vs. 78.1%, p = 0.06). Among the patients who 
suffered AMI during the follow-up period, there 
was a higher proportion of known diabetics (57% 
vs. 32.8%, p = 0.02), and an initial clinical presen-
tation as stable angina was more frequent than in 
patients who did not suffer infarction in follow-up 
(38.1 vs. 19.4, p = 0.03). Patients readmitted for 
infarction presented a higher average SYNTAX 
score, without statistical significance being reached 
(13.71 vs. 11.23, p = 0.15).
Readmission for HF was less frequent among 
the patients with normal glucose metabolism, 
although statistical significance was not reached, 
more frequent among the known diabetics (66.7% 
vs. 32.9%, p = 0.007) and in patients with a lower 
LVEF (45.53 ± 12.77 vs. 55.85 ± 11.40, p = 0.001). 
The SYNTAX score was higher in patients who 
presented HF, although without statistical signifi-
cance (11.22 vs. 14.93, p = 0.07).
The variables related with mortality in follow-
-up were age (70.76 ± 7.04 years in patients who 
died vs. 62.64 ± 10.78 in remaining patients, 
p = 0.007) and the SYNTAX score (18.11 ± 9.13 
vs. 11.12 ± 7.66, p = 0.001).
In the multivariate analysis (Table 4), pre-
-diabetes and newly detected diabetes were not 
predictors of any cardiovascular events in follow-up 
(Table 4). Among glucose metabolism impairments, 
only a history of known diabetes was an indepen-
dent predictor of revascularization (OR 2.03, 95% 
CI 1.09–3.77, p = 0.025), non-fatal AMI (OR 2.70, 
95% CI 1.10–6.60, p= 0.029) and of readmission for 
HF during follow-up (OR 3.82, 95% CI 1.21–12.03, 
p = 0.022).
Discussion
This prospective study shows high prevalence 
of impaired glucose metabolism in patients under-
going PCI and its connection to the incidence of 
cardiovascular events, with known diabetes as the 
only glucose metabolism impairment that is an in-
dependent predictor of revascularization, non-fatal 
infarction and HF during follow-up.
Eighty-one percent of the patients in the series 
presented impaired glucose metabolism, of which 
35.3% were previously diagnosed diabetics, 21.4% 
newly detected diabetics and 24.3% pre-diabetics, 
as defined by recently published ADA diagnostic 
criteria [8].
The prevalence of impaired glucose meta-
bolism described in previous studies [14–17] in 
patients with previously unknown CVD is high, 
between 16% and 32% of newly detected diabetics 
and 25–34% of pre-diabetics depending on the 
different series reported and the diagnostic crite-
rion employed. In our research, the prevalence of 
high impairment is similar to that which has been 
described, but it should be noted that the timing 
of the OGTT is important: the following morning, 
as in our research, or two weeks afterwards [14], 
since the results may be contradictory [18]. The 
reasons for this could be an increase in stress 
regulation for the coronary angiography and the 
OGTT, concomitant medication, inactivity and 
low-carbohydrate diet during the preceding days, 
as has been described [18].
The deleterious consequences of impaired 
glucose metabolism in patients with ACS and 
no known history of DM have been extensively 
Table 4. Multivariate analysis.
Odds ratio 95% CI P
Revascularization: Known diabetes 2.03 1.09–3.77 0.025
Unstable angina: Gender (male) 0.30 0.14–0.64 0.002
Non-fatal AMI: Known diabetes 2.70 1.10–6.60 0.029
Heart failure:
Known diabetes 3.82 1.21–12.03 0.022
ACS as clinical presentation 0.17 0.05–0.55 0.003
Ejection fraction 0.93 0.90–0.97 0.001
Cardiovascular mortality:
Age 1.07 1.00–1.14 0.04
SYNTAX score 1.07 1.00–1.14 0.02
CI — confidence interval; AMI — acute myocardial infarction; ACS — acute coronary syndrome
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described on many occasions in research that has 
carried out screening without use of the OGTT [19, 
20]. Studies carried out in the general population 
show the predictive capacity of the tolerance test 
for cardiovascular events and mortality [21, 22] and 
the OGTT has been used to diagnose DM [10, 11].
However, evidence about the prognostic infor-
mation provided by the tolerance test in ischemic 
patients after percutaneous coronary revasculariza-
tion is scarce. In 2004, Bartnik et al. [22] published 
research on a series of 168 AMI patients with no 
known history of DM. The presence of abnormal 
glucose tolerance, together with a history of heart 
attack, was the strongest predictor of cardiovascu-
lar events, with a median follow-up of 34 months. 
A short time later, the results of a series of 4,676 
patients from the Euro Heart Survey on diabetes 
and the heart were reported [23]. Known diabetes 
was the strongest predictor of events, followed by 
newly detected diabetes with a lower OR. However, 
impaired fasting glucose and glucose intolerance 
were not predictors of events in follow-up. De la 
Hera et al. [15] carried out a 12 month follow-up of 
662 ischemic patients (both stable and NSTE-ACS) 
who underwent PCI, with an OGTT administered 
to patients with no known history of DM 2 weeks 
after discharge. Newly detected DM was not 
a prognostic predictor in this series. The main dif-
ferences between these studies are the timing to 
do the OGTT and the context (PCI in modern era 
or previous era of myocardial infarction with low 
rate of revascularization): the day after PCI in the 
present study, 2 weeks later as stated by de la Hera 
et al. [15] (ambulatory setting post-PCI), or the day 
of discharge in old era of myocardial infarction as 
stated by Bartnik et al. [22].
It should therefore be considered that, although 
carrying out an OGTT on ischemic patients provi-
des relevant information [24, 25], PCI is probably 
not the most suitable context to extract prognostic 
information about the detection of impaired glucose 
metabolism that is useful in the short-term clinical 
management of the patient. The reasons for this 
may be methodological, as this is a population at 
low risk of cardiovascular events; they may also 
be physiopathological as more time is needed in 
the progression of diabetes for coronary lesions to 
be produced [26]; or finally, the diagnosis of these 
impairments may be due more to the situation of 
stress than to the underlying cardiac pathology 
(which alters the tolerance test results) [17] than 
to the etiopathogenic reasons that lead to DM.
The use of simpler, faster, and more reprodu-
cible screening tools such as fasting glucose and 
HbA1c, in conjunction with a global approach to 
other cardiovascular risk factors may be a more 
suitable focus within the context of PCI.
Conclusions
In conclusion, in patients undergoing PCI, 
carrying out screening for impaired glucose meta-
bolism by means of the determination of fasting glu-
cose and the OGTT allows the detection of a high 
proportion of glucose abnormalities regulations. 
However, among glucose metabolism disorders, 
previously known diabetes is the only independent 
predictor of cardiovascular events during follow-up.
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